Evoke Pharma Announces FDA Orange Book Listing Of New GIMOTI Patent
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma, Inc. announced that its new patent for GIMOTI nasal spray is now listed in the FDA's Orange Book, extending patent protection to 2029. This listing adds to the existing three patents for GIMOTI and reinforces the company's IP portfolio. The Orange Book listing aids in monitoring potential generic competition.
November 27, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evoke Pharma's GIMOTI nasal spray patent listing in the FDA Orange Book extends its protection and may deter generic competition, potentially enhancing the drug's commercial longevity.
The listing of the new GIMOTI patent in the FDA Orange Book is a significant development for Evoke Pharma. It extends the patent protection of the drug, which can be crucial in preventing generic competition and maintaining market exclusivity. This could lead to increased investor confidence in the company's ability to generate revenue from GIMOTI over a longer period, potentially having a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100